Aiming for the brain: a new thermogel-based drug delivery platform

Glioblastoma Multiforme (GBM) is one of the most lethal human cancer types, with a 5-year survival rate of approximately 5%. A key reason for this is usually considered its poor accessibility to systemically administered drugs that only limitedly overcome the Blood Brain Barrier, ultimately causing the likely dismal appearance of recurrences. Here, we comment on our successful use, in GBM preclinical models, of novel thermogel based drug-delivery platforms for loco-regional treatment of tumor recurrences after primary surgery. The innovation as well as the pitfalls of our processes are outlined and discussed with an eye towards potential advancements in the realm of personalized medicine applications.